SUBSCRIBE
Search JIM Advanced Search

Journal of Chinese Integrative Medicine ›› 2012, Vol. 10 ›› Issue (6): 635-640.doi: 10.3736/jcim20120606

• Original Clinical Research • Previous Articles     Next Articles

Influence of Chinese herbal medicine Feitai Capsule on completion or delay of chemotherapy in patients with stage ⅢB/Ⅳ non-small-cell lung cancer: a Randomized controlled trial

Shui-qiu Deng1, Xue-nong Ouyang2, Zong-yang Yu2, Xi-hu Dai 2, Xi Chen 2, Fang-zheng Fang2, Wen-wu Wang2, Zhi-zhen Liu2   

  1. 1. Department of Disease Prevention, Fuzhou General Hospital of Nanjing Military Region, Fuzhou 350025, Fujian Province, China
    2. Department of Oncology, Fuzhou General Hospital of Nanjing Military Region, Fuzhou 350025, Fujian Province, China
  • Received:2011-09-27 Accepted:2011-12-18 Online:2012-06-20 Published:2018-06-15
  • Contact: Xue-nong Ouyang

RichHTML

1

PDF (PC)

68

Like

Background: Chemotherapy completion rate can reflect the tolerance and compliance of patients to chemotherapy. Poor tolerance may result in delay or suspension of the comprehensive treatment plan, thus affect the efficacy of cancer treatment. Evaluating methods to improve the completion rate of chemotherapy and reduce the occurrence of delayed chemotherapy has gained increasing attention and is the significant area of study in the field of cancer treatment. Studies have shown that Chinese medicine combined with chemotherapy could improve the quality of life in patients with stage ⅢB/Ⅳ non-small-cell lung cancer (NSCLC).
Objective: To observe the effects of Feitai Capsule, a Chinese patent herbal drug, combined with chemotherapy in patients with stage ⅢB/Ⅳ NSCLC.DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONS: A total of 60 diagnosed stage IIIB/IV NSCLC patients from the Department of Oncology, Fuzhou General Hosipital of Najing Military Region were randomly divided into treatment group (30 cases) and control group (30 cases). Patients in the treatment group were treated with chemotherapy plus Feitai Capsule and patients in the control group only received chemotherapy. Both groups of patients were treated for 4 therapeutic cycles.MAIN OUTCOME MEASURES: The chemotherapy completion rate and the chemotherapy delay rate were observed in each cycle of treatment. The therapeutic efficacy was evaluated after 4 cycles.
Results: The chemotherapy completion rate was 96.42% in the treatment group, while that of the control group was 74.07%. The chemotherapy delay rate was 3.57% in the treatment group, while that of the control group was 14.8% (P=0.007 0). The disease control rate was 78.6% in the treatment group, while that of the control group was 59.3% (P=0.173 9).
Conclusion: Feitai Capsule can increase the chemotherapy completion rate in patients with stage ⅢB/Ⅳ NSCLC.

Key words: carcinoma, non-small-cell lung, drugs, Chinese herbal, antineoplastic combined chemotherapy protocols, randomized controlled trial

Table 1

Comparison of general information in patients between the two groups"

Item Total patients (N=55) Control group (n=27) Treatment group (n=28) χ2 Pvalue
Male (n, %) 47 24 (51.06%) 23 (48.94%) 0.503 0.705
Female 8 3 (37.5%) 5 (62.5%)
Age (Median (Q25, Q75), years) 60 55.7 (29, 72) 59.5 (36~74)
Smoking 31 15 (48.39%) 16 (51.61%) 0.014 1
Non-smoking 24 12 (50.0%) 12 (50.0%)
NSCLC stage
ⅢB 16 7 (43.75%) 9 (56.25%) 0.258 0.768
Ⅳ 39 20 (51.28%) 19 (65.52%)
Karnofsky
80 to 90 36 18 (50.0%) 18 (50.0%) 0.034
90 to 100 19 9 (47.37%) 10 (52.63%)

Figure 1

Flow diagram of this randomized trial"

Table 2

Chemotherapy completion rate and chemotherapy delay rate of the two groups (n, %)"

Group Chemotherapy completion rate Chemotherapy delay rate
Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 1 Cycle 2 Cycle 3 Cycle 4
Treatment 100 (28/28) 100 (28/28) 96.42 (27/28) 96.42 (27/28) 0 (0/28) 0 (0/28) 3.57 (1/28) 3.57 (1/28)
Control 100 (27/27) 96.29 (26/27) 88.88 (24/27) 74.07 (20/27) 0 (0/27) 0 (0/27) 7.4 (2/27) 14.8 (3/27)
[1] American Cancer Society . Cancer facts and figures 2006[M]. Atlanta: American Cancer Society, 2006: 13-14
[2] Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ , Thun MJ. American Cancer Society. Cancer statistics[J]. 2004; CA Cancer J Clin, 2004,54(1):8-29
[3] Lin LZ, Zhou DH, Zheng XT . Effect of traditional Chinese medicine in improving quality of life of patients with non-small cell lung cancer in late stage[J]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2006,26(5):389-393
林丽珠, 周岱翰, 郑心婷 . 中医药提高晚期非小细胞肺癌患者生存质量的临床观察[J]. 中国中西医结合杂志, 2006,26(5):389-393
[4] Zhou YM, Piao BK, Hou W, Lin HS, Hua BJ, Xiong L, Zheng HG . Clinical observation of Feiliuping ointment on immune state and prognosis in patients with non-small-cell lung cancer[J]. Zhongguo Zhong Yi Yao Xin Xi Za Zhi, 2008,15(5):78-79
doi: 10.3969/j.issn.1005-5304.2008.05.040
周雍明, 朴炳奎, 侯炜, 林洪生, 花宝金, 熊露, 郑红刚 . 肺瘤平膏改善非小细胞肺癌患者免疫状态及预后的临床观察[J]. 中国中医药信息杂志, 2008,15(5):78-79
doi: 10.3969/j.issn.1005-5304.2008.05.040
[5] Liu JX . Effect of Chinese medicine in maintaining quality of life of cancer patients[J]. Zhonghua Zhong Liu Za Zhi, 2002,24(3):309-310
doi: 10.3760/j.issn:0253-3766.2002.03.032
刘嘉湘 . 中医药维护癌症患者生存质量的作用[J]. 中华肿瘤杂志, 2002,24(3):309-310
doi: 10.3760/j.issn:0253-3766.2002.03.032
[6] Ye L, Ouyang XN, Dai XH, Yu ZY, Liu ZZ . Clinical effect of Feitai Capsule in the treatment for 60 cases with advanced non-small cell lung cancer with the syndrome of deficiency of vital energy and phlegm blood-stasis[J]. Zhongguo Zhong Liu, 2010,19(12):828-832
叶磊, 欧阳学农, 戴西湖, 余宗阳, 刘志臻 . 肺泰胶囊对晚期非小细胞肺癌“气虚痰瘀互结证”患者疗效评价[J]. 中国肿瘤, 2010,19(12):828-832
[7] Liu ZZ, Yu ZY, Ouyang XN, Dai XH, Chen X, Zhao ZQ, Wang WW, Li J, Tu H, Ye L, Yan Y . Effect of maintenance therapy with Feitai capsules in patients with advanced non-small cell lung cancer[J]. Lin Chuang Zhong Liu Xue Za Zhi, 2009,14(4):344-346
doi: 10.3969/j.issn.1009-0460.2009.04.014
刘志臻, 余宗阳, 欧阳学农, 戴西湖, 陈曦, 赵忠全, 王文武, 李捷, 涂华, 叶磊, 颜艳 . 中药复方肺泰胶囊维持治疗对中晚期非小细胞肺癌无进展生存期的影响[J]. 临床肿瘤学杂志, 2009,14(4):344-346
doi: 10.3969/j.issn.1009-0460.2009.04.014
[8] Han R. Cancer chemoprevention and drug treatment[M]. Beijing: Peking Union Medical College Press, 1995: 353-356
韩锐 . 肿瘤化学预防及药物治疗[M]. 北京: 中国协和医科大学出版社, 1995: 353-356
[9] DeVita VT, IIellman S Jr, Rosenberg SA. 癌——肿瘤学原理和实践. 徐从高, 张茂宏, 杨兴季主译.第5版[M]. 济南: 山东科学技术出版社, 2002: 355
DeVita VT, IIellman S Jr, Rosenberg SA . Cancer — Principles and practice of oncology. Translated by Xu CG, Zhang MH, Yang XJ.5th ed[M]. Jinan: Shandong Science and Technology Press, 2002: 355
[10] Goldie JH, Goldman AJ . A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate[J]. Cancer Treat Rep, 1979,63(11-12):1727-1733
[11] Wang RT, Shan BE, Li QX, Tang JF, Qiao F, Du XN, Li H, Ye J . Extracorporeal experimental study on immuno-modulatory activity of Astragalus membranaceus extract[J]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2002,22(6):453-456
王润田, 单保恩, 李巧霞, 唐建发, 乔芳, 杜肖娜, 李宏, 叶静 . 黄芪提取物免疫调节活性的体外实验研究[J]. 中国中西医结合杂志, 2002,22(6):453-456
[12] Zhang S, Mou XY, Wang HM, Jiang SJ . Enhancement of the cytotoxic effect of cytokine induced killers by dendritic cells pulsed with Astragalus polysaccharides[J]. Zhongguo Mian Yi Xue Za Zhi, 2009,25(2):140-142
张嵩, 牟晓燕, 王红梅, 姜淑娟 . 黄芪多糖诱导的树突状细胞增强CIK细胞的杀伤作用[J]. 中国免疫学杂志, 2009,25(2):140-142
[13] Hong G, Dai YH, Liu PX, Shen X, Wei YY, Li G . Advances in research on chemical constituents and pharmacological activities of Agrimonia pilosa[J]. Yao Xue Fu Wu Yu Yan Jiu, 2008,8(5):362-363
洪阁, 戴永红, 刘培勋, 沈秀, 魏永燕, 李根 . 仙鹤草化学成分和药理作用研究进展[J]. 药学服务与研究, 2008,8(5):362-363
[14] Ma LP, Zhao PR, Wang LX, Zhang SH . Inhibitory effects of Agrimonia pilosa Ledeb. water extract on Eca109 cells in vitro[J]. Zhengzhou Da Xue Xue Bao Yi Xue Ban, 2007,42(1):149-151
doi: 10.3969/j.issn.1671-6825.2007.01.057
马丽萍, 赵培荣, 王留兴, 张书红 . 仙鹤草水提液对食管癌Eca109细胞生长的抑制作用[J]. 郑州大学学报(医学版), 2007,42(1):149-151
doi: 10.3969/j.issn.1671-6825.2007.01.057
[15] Wen Y, Bi L, Zhang YB, Chen WP . Inhibitory effects of Agrimonia pilosa Ledeb. water extract on lung cancer A549 cells in vitro[J]. Zhong Yi Yao Xin Xi, 2009,26(5):33-35
doi: 10.3969/j.issn.1002-2406.2009.05.013
温雅, 毕蕾, 张义彪, 陈卫平 . 仙鹤草水提液对肺癌A549细胞增殖的抑制作用[J]. 中医药信息, 2009,26(5):33-35
doi: 10.3969/j.issn.1002-2406.2009.05.013
[16] Wang F, Yuan ST, Zhu DN . Active components of antitumor fraction from Sarcandra glabra[J]. Zhongguo Tian Ran Yao Wu, 2007,5(3):174-178
王菲, 袁胜涛, 朱丹妮 . 肿节风抗肿瘤活性部位的化学成分[J]. 中国天然药物, 2007,5(3):174-178
[17] Kang M, Tang AZ, Liang G, Yi X, Liu J . A study on the inhibition of Sarcandrea extracts on proliferation of nasopharyngeal carcinoma cell[J]. Guangxi Yi Ke Da Xue Xue Bao, 2008,25(3):347-349
康敏, 唐安洲, 梁钢, 易翔, 刘津 . 肿节风提取物抑制鼻咽癌细胞增殖的实验研究[J]. 广西医科大学学报, 2008,25(3):347-349
[1] Chiung-Hui Huang, Mei-Ling Yeh, Fang-Pey Chen, Daphne Wu. Low-level laser acupuncture reduces postoperative pain and morphine consumption in older patients with total knee arthroplasty: A randomized placebo-controlled trial. Journal of Integrative Medicine, 2022, 20(4): 321-328.
[2] Maryam Azimi, Hanieh Niayesh, Mahboobeh Raeiszadeh, Sedigheh Khodabandeh-shahraki. Efficacy of the herbal formula of Foeniculum vulgare and Rosa damascena on elderly patients with functional constipation: A double-blind randomized controlled tria. Journal of Integrative Medicine, 2022, 20(3): 230-236.
[3] Ubiratan Cardinalli Adler, Maristela Schiabel Adler, Ana Elisa Madureira Padula, Livia Mitchiguian Hotta, Amarilysde Toledo Cesar, José Nelson Martins Diniz, Helen de Freitas Santos, Edson Zangiacomi Martinez. Homeopathy for COVID-19 in primary care: A randomized, double-blind, placebo-controlled trial (COVID-Simile study). Journal of Integrative Medicine, 2022, 20(3): 221-229.
[4] Xin Wang, Wen-juan Song, Yi Ruan, Bing-chu Li, Can Lü, Nian Huang, Fan-fu Fang, Wei Gu. Core muscle functional strength training for reducing the risk of low-back pain in military recruits: An open-label randomized controlled trial. Journal of Integrative Medicine, 2022, 20(2): 145-152.
[5] Shu-yi Chen, Qun-wei Chen, Liu-mei Shou, Hong Pan, Shan-ming Ruan, Zhe-hao Liang, Qi-jin Shu. Stevens-Johnson syndrome/toxic epidermal necrolysis successfully treated with Chinese herbal medicine Pi-Yan-Ning: A case report. Journal of Integrative Medicine, 2021, 19(6): 555-560.
[6] Jia-jia Li, Qing Liang, Guang-chun Sun. Traditional Chinese medicine for prevention and treatment of hepatocellular carcinoma: A focus on epithelial-mesenchymal transition. Journal of Integrative Medicine, 2021, 19(6): 469-477.
[7] Xin Yin, Shu-bin Cai, Lan-ting Tao, Lu-ming Chen, Zhong-de Zhang, Su-hong Xiao, Arthur Yin Fan, Xu Zou. Recovery of a patient with severe COVID-19 by acupuncture and Chinese herbal medicine adjuvant to standard care. Journal of Integrative Medicine, 2021, 19(5): 460-466.
[8] Tong Zhao, Bing-jie Guo, Chu-lan Xiao, Jiao-jiao Chen, Can Lü, Fan-fu Fang, Bai Li. Aerobic exercise suppresses hepatocellular carcinoma by downregulating dynamin-related protein 1 through PI3K/AKT pathway. Journal of Integrative Medicine, 2021, 19(5): 418-427.
[9] Meng-zhu Zhao, Chen Zhao, Shuang-shuang Tu, Xu-xu Wei, Hong-cai Shang. Evaluating the methodology of studies conducted during the global COVID-19 pandemic: A systematic review of randomized controlled trials. Journal of Integrative Medicine, 2021, 19(4): 317-326.
[10] Si-chun Gu, Jie Zhou, Qing Ye, Can-xing Yuan. Pingchan granule for depressive symptoms in Parkinson’s disease: A randomized, double-blind, placebo-controlled trial. Journal of Integrative Medicine, 2021, 19(2): 120-128.
[11] Jie Wu, Shu-wei Duan, Hong-tao Yang, Yue-yi Deng, Wei Li, Ya-ni He, Zhao-hui Ni, Yong-li Zhan, Shan Lin, Zhi-yong Guo, Jun Zhu, Jing-ai Fang, Xu-sheng Liu, Li-hua Wang, Rong Wang, Nian-song Wang, Xiao-hong Cheng, Li-qun He, Ping Luo, Shi-ren Sun s, Ji-feng Sun, Ai-ping Yin, Geng-ru Jiang, Hong-yu Chen, Wen-hu Liu, Hong-li Lin, Meng Liang, Lu Ma, Ming Chen, Li-qun Song, Jian Chen, Qing Zhu, Chang-ying Xing, Yun Li, Ji-ning Gao, Rong-shan Li, Ying Li, Hao Zhang, Ying Lu, Qiao-ling Zhou, Jun-zhou Fu, Qiang He, Guang-yan Cai, Xiang-mei Chen. Efficacy and safety of Shenyankangfu Tablet, a Chinese patent medicine, for primary glomerulonephritis: A multicenter randomized controlled trial. Journal of Integrative Medicine, 2021, 19(2): 111-119.
[12] Ming-sheng Lyu, De-ying Li, Shao-zhong Zhou, Cheng-jun Ban, Jun Yan. Adult-onset Still's disease successfully treated with Chinese herbal medicine: A case report with 15-month follow-up. Journal of Integrative Medicine, 2020, 18(6): 530-534.
[13] Xian Wang, Xuan Yin, Xiu-tian Guo, Yan Wang, Wen-qi Jin, Ai-jun Mao, Lixing Lao, Zhang-jin Zhang, Jie Zhang, Shi-fen Xu. Effects of the pestle needle therapy, a type of acupoint stimulation, on post-hemorrhoidectomy pain: A randomized controlled trial. Journal of Integrative Medicine, 2020, 18(6): 492-498.
[14] Qing-lan Wang, Yan-yan Tao, Hong-dong Xie, Cheng-hai Liu, Ping Liu. Fuzheng Huayu recipe, a traditional Chinese compound herbal medicine, attenuates renal interstitial fibrosis via targeting the miR-21/PTEN/AKT axis. Journal of Integrative Medicine, 2020, 18(6): 505-513.
[15] Arthur Yin Fan, Sherman Gu, Sarah Faggert Alemi, Research Group for Evidence-based Chinese Medicine. Chinese herbal medicine for COVID-19: Current evidence with systematic review and meta-analysis. Journal of Integrative Medicine, 2020, 18(5): 385-394.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] Wei-xiong Liang. Problems-solving strategies in clinical treatment guideline for traditional Chinese medicine and integrative medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 1-4
[2] Zhao-guo Li. Discussion on English translation of commonly used sentences in traditional Chinese medicine: part one. Journal of Chinese Integrative Medicine, 2008, 6(1): 107-110
[3] Jun Hu, Jian-ping Liu. Non-invasive physical treatments for chronic/recurrent headache. Journal of Chinese Integrative Medicine, 2008, 6(1): 31
[4] Xue-mei Liu, Qi-fu Huang, Yun-ling Zhang, Jin-li Lou, Hong-sheng Liu, Hong Zheng. Effects of Tribulus terrestris L. saponion on apoptosis of cortical neurons induced by hypoxia-reoxygenation in rats. Journal of Chinese Integrative Medicine, 2008, 6(1): 45-50
[5] . Uniform requirements for manuscripts submitted to biomedical journals: Writing and editing for biomedical publication (Chinese version, part two). Journal of Chinese Integrative Medicine, 2010, 8(11): 1001-1005
[6] Daniel Weber, Janelle M Wheat, Geoffrey M Currie. Inflammation and cancer: Tumor initiation, progression and metastasis,and Chinese botanical medicines. Journal of Chinese Integrative Medicine, 2010, 8(11): 1006-1013
[7] Hong Liu , Guo-liang Zhang, Li Shen , Zhen Zeng, Bao-luo Zhou, Cheng-hai Liu, Guang Nie . Application and evaluation of a pseudotyped virus assay for screening herbs for anti-H5Nl avian influenza virus. Journal of Chinese Integrative Medicine, 2010, 8(11): 1036-1040
[8] Zhao-guo Li . A discussion of English translation of 1995 and 1997 Chinese National Standards of Traditional Chinese Medical Terminologies for Clinical Diagnosis and Treatment. Journal of Chinese Integrative Medicine, 2010, 8(11): 1090-1096
[9] Rui Jin, Bing Zhang. A complexity analysis of Chinese herbal property theory: the multiple formations of herbal property (Part 1). Journal of Chinese Integrative Medicine, 2012, 10(11): 1198-1205
[10] Hui-min Liu, Xian-bo Wang, Yu-juan Chang, Li-li Gu. Systematic review and meta-analysis of randomized controlled trials of integrative medicine therapy for treatment of chronic severe hepatitis. Journal of Chinese Integrative Medicine, 2012, 10(11): 1211-1228
Journal of Integrative Medicine, ISSN: 2095-4964 CN 31-2083/R
Copyright © Journal of Integrative Medicine
Powered by Beijing Magtech Co. Ltd
沪公网安备31010602003416号      沪ICP备18017633号-3